Strata Critical Medical, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description |
| 2.1(1) | Equity Purchase Agreement, dated as of August 1, 2025, among Blade Air Mobility, Inc., Trinity Medical Intermediate II, Inc., Blade Urban Air Mobility, Inc., Joby Aviation, Inc. and Joby Aero, Inc. |
| 2.2(2) | Purchase and Sale Agreement, dated as of September 16, 2025, among Strata Critical, Inc., Keystone Perfusion Services, LLC, and other parties named therein, dated August 20, 2025 |
| 3.1(3) | Second Amended and Restated Certificate of Incorporation of Blade Air Mobility, Inc. |
| 3.2(4) | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Blade Air Mobility, Inc. |
| 3.3(5) | Amended and Restated Bylaws of Strata Critical Medical, Inc. |
| 10.1(6) | Transition and Transaction Bonus Agreement, dated as of August 1, 2025, between Robert S. Wiesenthal and the Company +{ |
| 10.2(7) | Restrictive Covenant Agreement, dated as of August 29, 2025, between Strata Critical Medical, Inc. and Joby Aviation, Inc. { |
| 10.3(8) | Commercial Agreement, dated as of August 29, 2025 between Strata Critical Medical, Inc., Joby Aviation, Inc. and Joby Aero, Inc. |
| 10.4(9) | Form of Performance Stock Unit Agreement (EBITDA Earnout) Pursuant to the Strata Critical Medical, Inc. 2021 Omnibus Incentive Plan + |
| 10.5(10) | Form of Performance Stock Unit Agreement (2025 Co-CEO) Pursuant to the Strata Critical Medical, Inc. |
| 10.6(11) | Co-CEO Offer Letter with Melissa Tomkiel, dated August 28, 2025+ |
| 10.7(12) | Co-CEO Offer Letter with William Heyburn, dated August 28, 2025+ |
| 10.8* | Strata Critical Medical, Inc. Amended and Restated Change in Control Severance Plan+ |
| 10.9* | Strata Critical Medical, Inc. Flight Benefit Policy for Independent Directors, Co-Chief Executive Officers and Certain Other Officers+ |
| 31.1*(13) | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2*(13) | Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1*(13) | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002 |
| 32.2*(13) | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002 |
| 101.INS* | Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language (“Inline XBRL”) |
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.SCH* | XBRL Taxonomy Extension Schema Document |
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB* | XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
*Filed herewith
- Denotes a management contract or compensatory arrangement.
⸶ Pursuant to Item 601(b) of Regulation S-K, certain exhibits, schedules and similar attachments have been omitted;
exhibits, schedules and other attachments will be provided to the SEC upon request.
(1)Incorporated by reference to Exhibit 2.1 of our Form 8-K (file number 001-39046) filed on August 4, 2025.
(2)Incorporated by reference to Exhibit 2.1 of our Form 8-K (file number 001-39046) filed on September 16, 2025.
(3)Incorporated by reference to Exhibit 3.1 of our Form 8-K (file number 001-39046) filed on May 13, 2021.
(4)Incorporated by reference to Exhibit 3.1 of our Form 8-K (file number 001-39046) filed on August 29, 2025.
(5)Incorporated by reference to Exhibit 3.2 of our Form 8-K (file number 001-39046) filed on August 29, 2025.
(6)Incorporated by reference to Exhibit 10.1 of our Form 8-K (file number 001-39046) filed on August 4, 2025.
(7)Incorporated by reference to Exhibit 10.1 of our Form 8-K (file number 001-39046) filed on August 29, 2025.
(8)Incorporated by reference to Exhibit 10.2 of our Form 8-K (file number 001-39046) filed on August 29, 2025.
(9)Incorporated by reference to Exhibit 10.1 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.
(10)Incorporated by reference to Exhibit 10.2 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.
(11)Incorporated by reference to Exhibit 10.3 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.
(12)Incorporated by reference to Exhibit 10.4 of our Form 8-K/A (file number 001-39046) filed on August 29, 2025.
(13)This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.